User profiles for MICHAEL B. JAMESON
 | Michael B JamesonWaikato Hospital; University of Auckland Verified email at waikatodhb.health.nz Cited by 3696 |
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
Background Reduced-dose nivolumab in combination with standard-dose ipilimumab
improves objective response and progression-free survival compared with standard-dose …
improves objective response and progression-free survival compared with standard-dose …
Review of high‐dose intravenous vitamin C as an anticancer agent
In the 1970s, P auling and C ameron reported increased survival of patients with advanced
cancer treated with high‐dose intravenous ( IV ) vitamin C ( L ‐ascorbate, ascorbic acid). …
cancer treated with high‐dose intravenous ( IV ) vitamin C ( L ‐ascorbate, ascorbic acid). …
A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma
SM Rudman, MB Jameson, MJ McKeage… - Clinical Cancer …, 2011 - AACR
Purpose: AS1409 is a fusion protein comprising a humanized antibody BC1 linked to
interleukin-12 (IL-12). It is designed to deliver IL-12 to tumor-associated vasculature using an …
interleukin-12 (IL-12). It is designed to deliver IL-12 to tumor-associated vasculature using an …
Optimising selenium for modulation of cancer treatments
SO Evans, PF Khairuddin, MB Jameson - Anticancer research, 2017 - ar.iiarjournals.org
Selenium is an essential trace element involved in many biological processes that are mediated
through, at least, 25 selenoproteins expressed in humans. Extensive study of selenium …
through, at least, 25 selenoproteins expressed in humans. Extensive study of selenium …
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors
MB Jameson, D Rischin, M Pegram, J Gutheil… - Cancer chemotherapy …, 2010 - Springer
Purpose PR-104 is a “pre-prodrug” designed to be activated to a dinitrobenzamide nitrogen
mustard cytotoxin by nitroreduction in hypoxic regions of tumors. This study was conducted …
mustard cytotoxin by nitroreduction in hypoxic regions of tumors. This study was conducted …
Phase II study of ASA404 (vadimezan, 5, 6-dimethylxanthenone-4-acetic acid/DMXAA) 1800 mg/m2 combined with carboplatin and paclitaxel in previously untreated …
MJ McKeage, M Reck, MB Jameson, MA Rosenthal… - Lung cancer, 2009 - Elsevier
This single-arm phase II study evaluated the tumor-vascular disrupting agent ASA404 (vadimezan,
5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m 2 plus standard therapy of …
5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m 2 plus standard therapy of …
Impact of geriatric assessment on the management of older adults with head and neck cancer: a pilot study
M Neve, MB Jameson, S Govender… - Journal of geriatric …, 2016 - Elsevier
Objective Assess the utility of the G8 screening tool and CGA for older adults with head and
neck cancer. Methods Patients 65 years or older with a primary malignancy of the head and …
neck cancer. Methods Patients 65 years or older with a primary malignancy of the head and …
Phase IB trial of the anti-cancer stem cell DLL4-binding agent demcizumab with pemetrexed and carboplatin as first-line treatment of metastatic non-squamous …
…, B Markman, M Hidalgo, MJ Millward, MB Jameson… - Targeted Oncology, 2018 - Springer
Background Delta-like ligand 4-Notch (DLL4-Notch) signaling contributes to the maintenance
of chemotherapy-resistant cancer stem cells and tumor vasculature. Objective This phase …
of chemotherapy-resistant cancer stem cells and tumor vasculature. Objective This phase …
Long-term follow-up of standard-dose pembrolizumab plus reduced-dose ipilimumab in patients with advanced melanoma: KEYNOTE-029 part 1B
Purpose: Combination therapy with reduced-dose programmed death 1 inhibitor plus
standard-dose cytotoxic T-lymphocyte–associated antigen 4 inhibitor demonstrated efficacy, but …
standard-dose cytotoxic T-lymphocyte–associated antigen 4 inhibitor demonstrated efficacy, but …
5, 6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent
…, BC Baguley, P Kestell, M Ravic, MB Jameson - Clinical cancer …, 2006 - AACR
This phase I safety study aimed to identify the optimal dose of the vascular disrupting agent
5,6-dimethylxanthenone-4-acetic acid (DMXAA) for combination studies. Using a crossover …
5,6-dimethylxanthenone-4-acetic acid (DMXAA) for combination studies. Using a crossover …